ACA Pharma has signed an exclusive distribution agreement with Eagle Pharmaceuticals to commercialize Ryanodex® (dantrolene sodium for injection), used for treating and preventing malignant hyperthermia, and Barhemsys® (amisulpride injection), for preventing and treating postoperative nausea and vomiting (PONV), across Hong Kong, Macau, Singapore, and Greater China. Ryanodex has completed fast-track registration in Macau, with Barhemsys ongoing, alongside filings in Hong Kong and Singapore; ACA is also purs ...

Core Insights - Eagle Pharmaceuticals, Inc. has released its unaudited financial statements for the three months ended March 31, 2025, which are accessible on their investor relations website [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical trials, manufacturing, and commercialization [2] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [2] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (in Japan), and BYFAVO® and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [2] - The company's oncology and CNS/metabolic critical care pipeline features product candidates aimed at addressing underserved therapeutic areas across various disease states [2] - Eagle is focused on developing medicines that could integrate into the personalized medicine paradigm in cancer care [2]

Core Points - Eagle Pharmaceuticals, Inc. announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders scheduled for October 17, 2025 [1] - The company is delivering a Notice of Internet Availability of Proxy Materials to stockholders of record as of August 18, 2025 [2] - The proxy materials, including the Notice, proxy information statement, and proxy card, are accessible online [2] - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines [3] - The company's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® [3] - Eagle's pipeline includes oncology and CNS/metabolic critical care product candidates aimed at addressing underserved therapeutic areas [3]

Core Viewpoint - Eagle Pharmaceuticals, Inc. has appointed Abhinav "Abi" Jain as an independent member of its Board of Directors, which is part of a cooperation agreement with Nantahala Capital Management, a significant shareholder holding approximately 38% of the company's outstanding shares [1][2]. Group 1: Appointment Details - Abhinav Jain will serve as a Class III director with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders [1]. - Jain will also be a member of the Board's Compensation Committee and Nominating and Corporate Governance Committee [1]. - The cooperation agreement includes provisions for the appointment of a second independent director by May 15, 2026 [1][3]. Group 2: Background of Abhinav Jain - Jain is currently an Analyst at Nantahala, focusing on investments in specialty and generic pharmaceuticals [2]. - Prior to Nantahala, he was an Associate at Angelo, Gordon & Co., where he concentrated on private equity and structured credit investments [2]. - Jain holds a degree in Chemical-Biological Engineering from the Massachusetts Institute of Technology and an M.B.A. with honors in Finance and Entrepreneurial Management from The Wharton School [2]. Group 3: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company involved in research and development, clinical, manufacturing, and commercial activities [4]. - The company is dedicated to developing innovative medicines aimed at improving patients' lives, with a portfolio that includes products like PEMFEXY®, RYANODEX®, and others [4]. - Eagle's pipeline includes oncology and critical care candidates targeting underserved therapeutic areas, with a focus on personalized medicine in cancer care [4].

Core Points - Eagle Pharmaceuticals, Inc. will hold its 2025 Annual Meeting of Stockholders on October 17, 2025 [1] - The record date for stockholders to participate in the meeting is set for August 18, 2025, at 5 p.m. Eastern Time [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial sectors [3] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [3] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [3] - The oncology and critical care pipeline includes product candidates aimed at addressing underserved therapeutic areas across multiple disease states [3] - The company focuses on developing medicines that could be integrated into the personalized medicine paradigm in cancer care [3]

Core Viewpoint - Eagle Pharmaceuticals has entered into a royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA for a total of $69 million before transaction costs, providing immediate capital to the company [1][3][4]. Group 1: Transaction Details - The agreement involves Eagle receiving an upfront payment of $69 million in exchange for a specified amount of its royalty interest in BENDEKA's net sales for the quarter ending December 31, 2024, and 100% of the royalty interest thereafter, capped at 1.3 times the purchase price [4]. - The proceeds from the transaction will be used to fully repay an existing credit agreement, including a $27.5 million term loan and $25 million under a revolving credit facility, with remaining funds allocated for general corporate purposes [5]. Group 2: Product Information - BENDEKA is a ready-to-dilute liquid formulation of bendamustine, approved for treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) [2]. - The product is characterized by its low-volume (50 mL) and short infusion time (ten minutes) [2]. Group 3: Company Strategy and Future Plans - The company continues to invest in its R&D programs, including CAL02 for severe community-acquired bacterial pneumonia and EA 114 for hormone-receptor-positive metastatic breast cancer [6]. - The transaction is seen as a strategic move to enhance the company's financial position and support ongoing research initiatives [3]. Group 4: Advisory and Legal Support - Armentum Partners, LLC acted as the financial advisor for Eagle on this transaction, while Latham & Watkins LLP provided legal counsel to Eagle, and Gibson, Dunn & Crutcher LLP represented Blue Owl [7]. Group 5: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines with a portfolio that includes products like PEMFEXY®, RYANODEX®, and BENDEKA® [8]. - The company aims to address underserved therapeutic areas across multiple disease states and is committed to personalized medicine in cancer care [8].

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to increase the initial purchase price of each preferred share purchase right from $10.00 to $20.00, effective immediately, in response to significant dislocation in the trading price of its common stock [1][2]. Group 1: Rights Plan Details - The Rights Plan is designed to penalize any person or group acquiring 10% or more of the company's common stock without Board approval, with a higher threshold of 15% for passive institutional investors [2]. - The amendment increases the potential dilution an Acquiring Person would face if the Rights Plan is triggered, thereby protecting stockholders' long-term investment value [2]. - The Rights Plan will automatically expire on October 30, 2025, unless earlier redeemed or exchanged by the company [3]. Group 2: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial operations [4]. - The company is focused on developing innovative medicines, particularly in oncology and critical care, with products like PEMFEXY®, RYANODEX®, and others in its pipeline [4].

Overview of the Recent Transaction - On October 3, 2024, Union Square Park Capital Management acquired 1,191,490 shares of Eagle Pharmaceuticals Inc at $1.99 per share, impacting the firm's portfolio by 2.06% [1] - This acquisition establishes a substantial position in Eagle Pharmaceuticals for Union Square Park Capital Management, which has a total equity of $113 million and focuses on Consumer Cyclical and Real Estate sectors [1] Company Profile - Eagle Pharmaceuticals Inc is a specialty pharmaceutical company based in the USA, focusing on injectable products for critical care, orphan diseases, and oncology since its IPO on February 12, 2014 [3] - The current market capitalization of Eagle Pharmaceuticals is $12.96 million, with a stock price of $1 [3] Financial and Market Analysis - Eagle Pharmaceuticals has faced significant market challenges, with a stock price decline of 49.75% since the transaction, a 93.55% drop since its IPO, and a year-to-date decrease of 82.33% [4] - The company holds a GF Score of 60/100, indicating potential concerns about its future performance, with a Profitability Rank and Financial Strength of 7/10, but a lower Growth Rank of 3/10 [4] Impact of the Trade on Union Square Park Capital Management's Portfolio - The acquisition of Eagle Pharmaceuticals shares accounts for 2.06% of Union Square Park Capital Management's total investments and 9.17% of its holdings in the stock, diversifying the firm's investments and increasing exposure to the pharmaceutical sector [5] Market Reaction and Stock Performance Post-Transaction - Following the transaction, Eagle Pharmaceuticals' stock has not performed well, facing significant declines and valuation challenges, compounded by insufficient data for evaluation against the GF Value [6] Future Outlook and Strategic Positioning - The investment in Eagle Pharmaceuticals likely reflects a belief in the company's long-term potential despite current market struggles, positioning for a potential turnaround or significant developments that could lead to future value [7] Conclusion - The acquisition of Eagle Pharmaceuticals shares by Union Square Park Capital Management is a strategic move that aligns with its investment strategy, adding a new dimension to its portfolio despite the current performance challenges [8]

WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that data from the Company's Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting ("PONV") will be presented at the upcoming American Society of PeriAnesthesia Nurses (ASPAN) 2024 National Conference, which is being held April 14-18, 2024, in Orlando, Florida. The data being presented relate ...

If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX. There is no cost or obligation to you. NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investig ...